Clinical Trial Update: Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and immunogenicity of two formulations of a meningococcal B recombinant vaccine in healthy infants; results from …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal B Recombinant Vaccine (Meningococcal B recombinant vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 2 | Status: COMPLETED | Results posted: 2015-03-06